Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,124

Participants

Timeline

Start Date

June 27, 2013

Primary Completion Date

August 30, 2017

Study Completion Date

August 30, 2017

Conditions

Anogenital Human Papilloma Virus InfectionCondyloma Acuminata

Interventions

BIOLOGICAL

V501

Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant

BIOLOGICAL

Placebo

Formulated with AAHS adjuvant

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01862874 - Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) | Biotech Hunter | Biotech Hunter